| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aims and Scope/Editorial Board/Publishing Details
|
|
|
2006
|
34 |
2 |
p. CO2-
1 p.
|
artikel
|
| 2 |
A vision of a world without polio: The OPV cessation strategy
|
Heymann, David L.
|
|
2006
|
34 |
2 |
p. 75-79
5 p.
|
artikel
|
| 3 |
Development of inactivated poliovirus vaccine derived from Sabin strains
|
Simizu, B.
|
|
2006
|
34 |
2 |
p. 151-154
4 p.
|
artikel
|
| 4 |
Developments in the production and quality control of poliovirus vaccines – Historical perspectives
|
Furesz, J.
|
|
2006
|
34 |
2 |
p. 87-90
4 p.
|
artikel
|
| 5 |
First decade (1950–1960) of studies and trials with the polio vaccine
|
Koprowski, Hilary
|
|
2006
|
34 |
2 |
p. 81-86
6 p.
|
artikel
|
| 6 |
Gaps in scientific knowledge for the post eradication world
|
Minor, Philip
|
|
2006
|
34 |
2 |
p. 167-170
4 p.
|
artikel
|
| 7 |
Interrupting poliovirus transmission – New solutions to an old problem
|
Aylward, R. Bruce
|
|
2006
|
34 |
2 |
p. 133-139
7 p.
|
artikel
|
| 8 |
John Beale 1923–2005
|
Petricciani, John
|
|
2006
|
34 |
2 |
p. 175-
1 p.
|
artikel
|
| 9 |
Licensing of monovalent OPV1 vaccine
|
Farag, May Mahmoud
|
|
2006
|
34 |
2 |
p. 145-149
5 p.
|
artikel
|
| 10 |
Manufacturing and supply of monovalent oral polio vaccines
|
Graf, Hugues
|
|
2006
|
34 |
2 |
p. 141-144
4 p.
|
artikel
|
| 11 |
No evidence for prolonged excretion of polioviruses in persons with residual paralytic poliomyelitis in Ethiopia, Pakistan and Guatemala
|
Khan, Aamir J.
|
|
2006
|
34 |
2 |
p. 113-116
4 p.
|
artikel
|
| 12 |
Polio vaccine development in Canada: Contributions to global polio eradication
|
Barreto, Luis
|
|
2006
|
34 |
2 |
p. 91-101
11 p.
|
artikel
|
| 13 |
Polio vaccine: The first 50 years and beyond
|
Griffiths, Elwyn
|
|
2006
|
34 |
2 |
p. 73-74
2 p.
|
artikel
|
| 14 |
Polio vaccine: The first 50 years and beyond
|
Wood, D.J.
|
|
2006
|
34 |
2 |
p. 171-174
4 p.
|
artikel
|
| 15 |
Poliovirus excretion in Guatemalan adults and children with HIV infection and children with cancer
|
Asturias, Edwin J.
|
|
2006
|
34 |
2 |
p. 109-112
4 p.
|
artikel
|
| 16 |
Post-eradication poliovirus facility-associated community risks
|
Dowdle, Walter R.
|
|
2006
|
34 |
2 |
p. 127-132
6 p.
|
artikel
|
| 17 |
Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view
|
Duchêne, Michel
|
|
2006
|
34 |
2 |
p. 163-166
4 p.
|
artikel
|
| 18 |
Regulation and standardization of IPV and IPV combination vaccines
|
Baca-Estrada, Maria
|
|
2006
|
34 |
2 |
p. 159-161
3 p.
|
artikel
|
| 19 |
Surveillance for polioviruses
|
Hovi, Tapani
|
|
2006
|
34 |
2 |
p. 123-126
4 p.
|
artikel
|
| 20 |
Technology transfer of Sabin-IPV to new developing country markets
|
Kreeftenberg, Hans
|
|
2006
|
34 |
2 |
p. 155-158
4 p.
|
artikel
|
| 21 |
Vaccine-derived polioviruses
|
Agol, Vadim I.
|
|
2006
|
34 |
2 |
p. 103-108
6 p.
|
artikel
|
| 22 |
Vaccine-derived poliovirus from long term excretors and the end game of polio eradication
|
Martín, Javier
|
|
2006
|
34 |
2 |
p. 117-122
6 p.
|
artikel
|
Tijdschrift beschrijving